Featured Research

from universities, journals, and other organizations

Diabetes drug target identified

Date:
May 21, 2012
Source:
University of Cincinnati Academic Health Center
Summary:
New research points to the naturally produced protein apolipoprotein A-IV as a potential target for a new diabetes therapeutic.

New research from the University of Cincinnati (UC) points to the naturally produced protein apolipoprotein A-IV (apoA-IV) as a potential target for a new diabetes therapeutic.

Patrick Tso, PhD, professor in the UC Department of Pathology and Laboratory Medicine, has published research on the ability of apoA-IV to reduce blood sugar levels and enhance insulin secretion.

The results appear the week of May 21, 2012, in the online early edition of Proceedings of the National Academy of Sciences.

ApoA-IV is secreted by the small intestine in response to fat absorption. Previous studies have shown apoA-IV to be elevated in humans following gastric bypass -- coinciding with improvement in symptoms for diabetes.

The Tso team found that mice deficient in apoA-IV had impaired glucose tolerance (insulin was not secreted to move glucose from the blood stream). These mice also developed diabetes when continuously fed a high-fat diet. When injected with apoA-IV, these same mice showed improved insulin response to glucose, despite a diet high in fat.

Tso's team also tested the response to injected apoA-IV in diabetic mice and found it reduced glucose levels among that group as well.

Tso says their research shows apoA-IV to behave similar to an incretin -- a gastrointestinal hormone causing an increased release of insulin after eating to combat the onset of elevated blood glucose. Two well-known incretins that have been used in the development of existing diabetes medications include gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1).

"The problem with both of these incretins is that they are short-lived -- lasting only for minutes -- and are quickly inactivated by an enzyme," says Tso. "They have also been linked to hypoglycemia, or low blood sugar, when administered when the body has a low glucose concentration. The challenge is to find something safer with a longer half-life."

Tso says apoA-IV has a long half-life (between seven and eight hours) and that tests in his lab showed it to have no effect on glucose levels when administered at low glucose concentrations. Instead, he says, it seems to function to normalize glucose.

The University of Cincinnati has licensed this research finding to a startup biotech company, Apofore Corporation, formed by HealthCare Ventures of Cambridge, Mass. Apofore will further study apoA-IV in humans in an effort to develop a novel diabetes therapeutic.

Tso's research was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

Co-authors include Sean Davidson, PhD, Tammy Kindel, Alison Kohan, Silvana Obici, PhD, Fei Wang and Stephen Woods, PhD, all from the University of Cincinnati; and Kathryn Corbin and Craig Nunemaker of the University of Virginia, Charlottesville.


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fei Wang, Alison B. Kohan, Tammy L. Kindel, Kathryn L. Corbin, Craig S. Nunemaker, Silvana Obici, Stephen C. Woods, W. Sean Davidson, and Patrick Tso. Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. PNAS, May 22, 2012 DOI: 10.1073/pnas.1201433109

Cite This Page:

University of Cincinnati Academic Health Center. "Diabetes drug target identified." ScienceDaily. ScienceDaily, 21 May 2012. <www.sciencedaily.com/releases/2012/05/120521163847.htm>.
University of Cincinnati Academic Health Center. (2012, May 21). Diabetes drug target identified. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2012/05/120521163847.htm
University of Cincinnati Academic Health Center. "Diabetes drug target identified." ScienceDaily. www.sciencedaily.com/releases/2012/05/120521163847.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins